应用替莫唑胺对照司莫司丁治疗恶性脑胶质瘤的疗效观察  

A clinical effect of temozolomide vs. semustine in patients with malignant gliomas

作　　者：曾宪起[1] 申长虹[1] 浦佩玉[1] 杨树源[1] 

机构地区：[1]天津医科大学总医院神经外科

出　　处：《中华神经外科杂志》2006年第4期204-207,共4页Chinese Journal of Neurosurgery

摘　　要：目的应用替莫唑胺(TMZ)以司莫司丁(CCNU)作为对照研究两者对恶性脑胶质瘤化疗的有效性。方法一年内入组合格患者55例,随机分成两组,按体表面积分别给以两种药物化疗并每月进行临床随访、定期复查头颅强化CT或MRI与化疗前资料比较判断病情变化。结果影像所示肿瘤实体的缓解率TMZ组为44．74％,CCNU组为11．77％,P=0．017。临床功能改善率TMZ 组为53％,CCNU组为12％,P=0．017。结论 TMZ比CCNU有较高的缓解率,更好的改善临床功能,可有效的提高生活质量。希望更长期更广泛的研究验证和改进本试验。Objective A clinical study was performed to determine the efficacy of temozolomide （TMZ） vs. semustine（CCNU） in patients with malignant gliomas. Methods 55 eligible patients were randomized to divide into two groups during one year. TMZ and CCNU were administered respectively every 28 days according to body surface area. Meantime, clinical experience should be performed every a month, and contrast- enhanced CT scan or GD- MRI was performed to evaluate the image-based progression comparing with the image before chemotherapy; which to evaluate disease progression. Results Imagebased respond rates were 44. 74% in TNZ group and 11.77% in CCNU group, P =0. 017. 53% of patients experienced a clinical benefit with TMZ treatment, and 12% with CCNU, P =0. 017. Conclusions TMZ showed more efficient object respond rate compared with CCNU and better clinical experience improvement with improving effectively quality of life. A longer time and more comprehensive trial are warranted to prove and modify this study.

关 键 词：替莫唑胺 TMZ 司莫司丁 CCNU 恶性脑胶质瘤 

分 类 号：R739.4[医药卫生—肿瘤]